Role of Xingnaojing Injection in treating acute cerebral hemorrhage: A systematic review and meta-analysis
Xingnaojing injection (XNJi) is widely used for acute cerebral hemorrhage. However, the efficacy of XNJi for acute cerebral hemorrhage has not been comprehensively proved by systematic analysis yet. Therefore, it is essential to evaluate the efficacy and safety of XNJi in an evidence-based method. S...
Gespeichert in:
| Veröffentlicht in: | Medicine (Baltimore) 2020-04, Vol.99 (15), p.e19648-e19648 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e19648 |
|---|---|
| container_issue | 15 |
| container_start_page | e19648 |
| container_title | Medicine (Baltimore) |
| container_volume | 99 |
| creator | Ma, Xiao Wang, Tao Wen, Jianxia Wang, Jian Zeng, Nan Zou, Wenjun Yang, Yuxue |
| description | Xingnaojing injection (XNJi) is widely used for acute cerebral hemorrhage. However, the efficacy of XNJi for acute cerebral hemorrhage has not been comprehensively proved by systematic analysis yet. Therefore, it is essential to evaluate the efficacy and safety of XNJi in an evidence-based method.
Six databases were searched with XNJi used for acute cerebral hemorrhage in randomized controlled trials (RCTs). Meta-analysis was performed by Review Manager 5.3. The efficacy rate, brain edema, cerebral hematoma, neurological deficit score, hs-crp, Glasgow Coma Scale (GCS), and activities of daily living (ADL) were systematically evaluated. The Cochrane risk of bias was used to evaluate the methodological quality of eligible studies.
This study is registered with PROSPERO (CRD42018098737). Twenty-nine studies with a total of 2638 patients were included in this meta-analysis. Compared with conventional treatment, XNJi got higher efficacy rate (OR = 3.37, 95% CI [2.65, 4.28], P |
| doi_str_mv | 10.1097/MD.0000000000019648 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7220447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32282713</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4052-3582dbaf4e17bf5d09e79c2a8d5faf6e98b6a1b0f5a17b47673716d267bc08133</originalsourceid><addsrcrecordid>eNpdkN1u1DAQhS1ERZfCEyAhv0Ba_8YJF0hVC6VSKyQEEnfWxJlssiR2ZXu72rfH7UL5mZvRjL9zxjqEvOHslLPWnN1enrI_xdtaNc_IimtZV7oMz8mKMaEr0xp1TF6mtCmQNEK9IMdSiEYYLldk8yXMSMNAv09-7SFsSqPXfoMuT8HTydMcEfLDFtw2I3UYsYsw0xGXEOMIa3xHz2nap4xLAR2NeD_hjoLv6YIZKvAw79OUXpGjAeaEr3_1E_Lt44evF5-qm89X1xfnN5VTTItK6kb0HQwKuekG3bMWTesENL0eYKixbboaeMcGDQVQpjbS8LoXtekca7iUJ-T9wfdu2y3YO_S5_NfexWmBuLcBJvvvi59Guw731gjBlDLFQB4MXAwpRRyetJzZh-jt7aX9P_qievv32SfN76wLoA7ALswZY_oxb3cY7Ygw5_HRT5tWVIIJxhRnrCobIeRPABKRHg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Role of Xingnaojing Injection in treating acute cerebral hemorrhage: A systematic review and meta-analysis</title><source>Wolters Kluwer Open Health</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Ma, Xiao ; Wang, Tao ; Wen, Jianxia ; Wang, Jian ; Zeng, Nan ; Zou, Wenjun ; Yang, Yuxue</creator><creatorcontrib>Ma, Xiao ; Wang, Tao ; Wen, Jianxia ; Wang, Jian ; Zeng, Nan ; Zou, Wenjun ; Yang, Yuxue</creatorcontrib><description><![CDATA[Xingnaojing injection (XNJi) is widely used for acute cerebral hemorrhage. However, the efficacy of XNJi for acute cerebral hemorrhage has not been comprehensively proved by systematic analysis yet. Therefore, it is essential to evaluate the efficacy and safety of XNJi in an evidence-based method.
Six databases were searched with XNJi used for acute cerebral hemorrhage in randomized controlled trials (RCTs). Meta-analysis was performed by Review Manager 5.3. The efficacy rate, brain edema, cerebral hematoma, neurological deficit score, hs-crp, Glasgow Coma Scale (GCS), and activities of daily living (ADL) were systematically evaluated. The Cochrane risk of bias was used to evaluate the methodological quality of eligible studies.
This study is registered with PROSPERO (CRD42018098737). Twenty-nine studies with a total of 2638 patients were included in this meta-analysis. Compared with conventional treatment, XNJi got higher efficacy rate (OR = 3.37, 95% CI [2.65, 4.28], P < .00001). Moreover, XNJi showed significant enhancement of efficacy rate via subgroup analysis in course and dosage. In addition, XNJi demonstrated significant improvement in Chinese stroke scale (CSS) and National Institutes of Health Stroke Scale (NHISS) (mean difference [MD] = -4.74, 95% CI [-5.89, -3.60], P < .00001; MD = -4.45, 95% CI [-5.49, -3.41], P < .00001), GCS (MD = 2.72, 95% CI [2.09, 3.35], P < .00001). It also remarkably decreased the level of hs-crp (MD = -6.50, 95% CI [-7.79, -5.21], P < .00001), enhanced ADL (MD = 20.38, 95% CI [17.98, 22.79], P < .00001), and alleviated hematoma and edema (MD = -2.53, 95% CI [-4.75, -0.31] P < .05; MD = -1.74 95% CI [-2.42, -1.07] P < .00001) compared with conventional treatment.
XNJi is effective in treating acute cerebral hemorrhage with significant improvement of CSS, NHISS and impairment of hs-crp, hematoma, and edema compared with conventional treatment. Moreover, XNJi got remarkable efficacy at the dose of 20, 30, 60 mL and from 7 to 28 days. No serious adverse reactions occurred. These results were mainly based on small-sample and low-quality studies. Therefore, more rigorous, large-scale RCTs were further needed to confirm its efficacy, safety, and detailed characteristic of application.]]></description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000019648</identifier><identifier>PMID: 32282713</identifier><language>eng</language><publisher>United States: the Author(s). Published by Wolters Kluwer Health, Inc</publisher><subject>Activities of Daily Living ; Acute Disease ; Adult ; Aged ; Aged, 80 and over ; Brain Edema - epidemiology ; C-Reactive Protein - analysis ; C-Reactive Protein - drug effects ; Cerebral Hemorrhage - drug therapy ; Cerebral Hemorrhage - epidemiology ; Drugs, Chinese Herbal - administration & dosage ; Drugs, Chinese Herbal - adverse effects ; Drugs, Chinese Herbal - therapeutic use ; Female ; Glasgow Coma Scale - statistics & numerical data ; Hematoma ; Humans ; Injections ; Male ; Middle Aged ; Nervous System Diseases - epidemiology ; Nervous System Diseases - physiopathology ; Randomized Controlled Trials as Topic ; Systematic Review And Meta-Analysis</subject><ispartof>Medicine (Baltimore), 2020-04, Vol.99 (15), p.e19648-e19648</ispartof><rights>the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4052-3582dbaf4e17bf5d09e79c2a8d5faf6e98b6a1b0f5a17b47673716d267bc08133</citedby><cites>FETCH-LOGICAL-c4052-3582dbaf4e17bf5d09e79c2a8d5faf6e98b6a1b0f5a17b47673716d267bc08133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220447/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220447/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32282713$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ma, Xiao</creatorcontrib><creatorcontrib>Wang, Tao</creatorcontrib><creatorcontrib>Wen, Jianxia</creatorcontrib><creatorcontrib>Wang, Jian</creatorcontrib><creatorcontrib>Zeng, Nan</creatorcontrib><creatorcontrib>Zou, Wenjun</creatorcontrib><creatorcontrib>Yang, Yuxue</creatorcontrib><title>Role of Xingnaojing Injection in treating acute cerebral hemorrhage: A systematic review and meta-analysis</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description><![CDATA[Xingnaojing injection (XNJi) is widely used for acute cerebral hemorrhage. However, the efficacy of XNJi for acute cerebral hemorrhage has not been comprehensively proved by systematic analysis yet. Therefore, it is essential to evaluate the efficacy and safety of XNJi in an evidence-based method.
Six databases were searched with XNJi used for acute cerebral hemorrhage in randomized controlled trials (RCTs). Meta-analysis was performed by Review Manager 5.3. The efficacy rate, brain edema, cerebral hematoma, neurological deficit score, hs-crp, Glasgow Coma Scale (GCS), and activities of daily living (ADL) were systematically evaluated. The Cochrane risk of bias was used to evaluate the methodological quality of eligible studies.
This study is registered with PROSPERO (CRD42018098737). Twenty-nine studies with a total of 2638 patients were included in this meta-analysis. Compared with conventional treatment, XNJi got higher efficacy rate (OR = 3.37, 95% CI [2.65, 4.28], P < .00001). Moreover, XNJi showed significant enhancement of efficacy rate via subgroup analysis in course and dosage. In addition, XNJi demonstrated significant improvement in Chinese stroke scale (CSS) and National Institutes of Health Stroke Scale (NHISS) (mean difference [MD] = -4.74, 95% CI [-5.89, -3.60], P < .00001; MD = -4.45, 95% CI [-5.49, -3.41], P < .00001), GCS (MD = 2.72, 95% CI [2.09, 3.35], P < .00001). It also remarkably decreased the level of hs-crp (MD = -6.50, 95% CI [-7.79, -5.21], P < .00001), enhanced ADL (MD = 20.38, 95% CI [17.98, 22.79], P < .00001), and alleviated hematoma and edema (MD = -2.53, 95% CI [-4.75, -0.31] P < .05; MD = -1.74 95% CI [-2.42, -1.07] P < .00001) compared with conventional treatment.
XNJi is effective in treating acute cerebral hemorrhage with significant improvement of CSS, NHISS and impairment of hs-crp, hematoma, and edema compared with conventional treatment. Moreover, XNJi got remarkable efficacy at the dose of 20, 30, 60 mL and from 7 to 28 days. No serious adverse reactions occurred. These results were mainly based on small-sample and low-quality studies. Therefore, more rigorous, large-scale RCTs were further needed to confirm its efficacy, safety, and detailed characteristic of application.]]></description><subject>Activities of Daily Living</subject><subject>Acute Disease</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Brain Edema - epidemiology</subject><subject>C-Reactive Protein - analysis</subject><subject>C-Reactive Protein - drug effects</subject><subject>Cerebral Hemorrhage - drug therapy</subject><subject>Cerebral Hemorrhage - epidemiology</subject><subject>Drugs, Chinese Herbal - administration & dosage</subject><subject>Drugs, Chinese Herbal - adverse effects</subject><subject>Drugs, Chinese Herbal - therapeutic use</subject><subject>Female</subject><subject>Glasgow Coma Scale - statistics & numerical data</subject><subject>Hematoma</subject><subject>Humans</subject><subject>Injections</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nervous System Diseases - epidemiology</subject><subject>Nervous System Diseases - physiopathology</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Systematic Review And Meta-Analysis</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkN1u1DAQhS1ERZfCEyAhv0Ba_8YJF0hVC6VSKyQEEnfWxJlssiR2ZXu72rfH7UL5mZvRjL9zxjqEvOHslLPWnN1enrI_xdtaNc_IimtZV7oMz8mKMaEr0xp1TF6mtCmQNEK9IMdSiEYYLldk8yXMSMNAv09-7SFsSqPXfoMuT8HTydMcEfLDFtw2I3UYsYsw0xGXEOMIa3xHz2nap4xLAR2NeD_hjoLv6YIZKvAw79OUXpGjAeaEr3_1E_Lt44evF5-qm89X1xfnN5VTTItK6kb0HQwKuekG3bMWTesENL0eYKixbboaeMcGDQVQpjbS8LoXtekca7iUJ-T9wfdu2y3YO_S5_NfexWmBuLcBJvvvi59Guw731gjBlDLFQB4MXAwpRRyetJzZh-jt7aX9P_qievv32SfN76wLoA7ALswZY_oxb3cY7Ygw5_HRT5tWVIIJxhRnrCobIeRPABKRHg</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Ma, Xiao</creator><creator>Wang, Tao</creator><creator>Wen, Jianxia</creator><creator>Wang, Jian</creator><creator>Zeng, Nan</creator><creator>Zou, Wenjun</creator><creator>Yang, Yuxue</creator><general>the Author(s). Published by Wolters Kluwer Health, Inc</general><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20200401</creationdate><title>Role of Xingnaojing Injection in treating acute cerebral hemorrhage: A systematic review and meta-analysis</title><author>Ma, Xiao ; Wang, Tao ; Wen, Jianxia ; Wang, Jian ; Zeng, Nan ; Zou, Wenjun ; Yang, Yuxue</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4052-3582dbaf4e17bf5d09e79c2a8d5faf6e98b6a1b0f5a17b47673716d267bc08133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Activities of Daily Living</topic><topic>Acute Disease</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Brain Edema - epidemiology</topic><topic>C-Reactive Protein - analysis</topic><topic>C-Reactive Protein - drug effects</topic><topic>Cerebral Hemorrhage - drug therapy</topic><topic>Cerebral Hemorrhage - epidemiology</topic><topic>Drugs, Chinese Herbal - administration & dosage</topic><topic>Drugs, Chinese Herbal - adverse effects</topic><topic>Drugs, Chinese Herbal - therapeutic use</topic><topic>Female</topic><topic>Glasgow Coma Scale - statistics & numerical data</topic><topic>Hematoma</topic><topic>Humans</topic><topic>Injections</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nervous System Diseases - epidemiology</topic><topic>Nervous System Diseases - physiopathology</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Systematic Review And Meta-Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ma, Xiao</creatorcontrib><creatorcontrib>Wang, Tao</creatorcontrib><creatorcontrib>Wen, Jianxia</creatorcontrib><creatorcontrib>Wang, Jian</creatorcontrib><creatorcontrib>Zeng, Nan</creatorcontrib><creatorcontrib>Zou, Wenjun</creatorcontrib><creatorcontrib>Yang, Yuxue</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ma, Xiao</au><au>Wang, Tao</au><au>Wen, Jianxia</au><au>Wang, Jian</au><au>Zeng, Nan</au><au>Zou, Wenjun</au><au>Yang, Yuxue</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of Xingnaojing Injection in treating acute cerebral hemorrhage: A systematic review and meta-analysis</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>99</volume><issue>15</issue><spage>e19648</spage><epage>e19648</epage><pages>e19648-e19648</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract><![CDATA[Xingnaojing injection (XNJi) is widely used for acute cerebral hemorrhage. However, the efficacy of XNJi for acute cerebral hemorrhage has not been comprehensively proved by systematic analysis yet. Therefore, it is essential to evaluate the efficacy and safety of XNJi in an evidence-based method.
Six databases were searched with XNJi used for acute cerebral hemorrhage in randomized controlled trials (RCTs). Meta-analysis was performed by Review Manager 5.3. The efficacy rate, brain edema, cerebral hematoma, neurological deficit score, hs-crp, Glasgow Coma Scale (GCS), and activities of daily living (ADL) were systematically evaluated. The Cochrane risk of bias was used to evaluate the methodological quality of eligible studies.
This study is registered with PROSPERO (CRD42018098737). Twenty-nine studies with a total of 2638 patients were included in this meta-analysis. Compared with conventional treatment, XNJi got higher efficacy rate (OR = 3.37, 95% CI [2.65, 4.28], P < .00001). Moreover, XNJi showed significant enhancement of efficacy rate via subgroup analysis in course and dosage. In addition, XNJi demonstrated significant improvement in Chinese stroke scale (CSS) and National Institutes of Health Stroke Scale (NHISS) (mean difference [MD] = -4.74, 95% CI [-5.89, -3.60], P < .00001; MD = -4.45, 95% CI [-5.49, -3.41], P < .00001), GCS (MD = 2.72, 95% CI [2.09, 3.35], P < .00001). It also remarkably decreased the level of hs-crp (MD = -6.50, 95% CI [-7.79, -5.21], P < .00001), enhanced ADL (MD = 20.38, 95% CI [17.98, 22.79], P < .00001), and alleviated hematoma and edema (MD = -2.53, 95% CI [-4.75, -0.31] P < .05; MD = -1.74 95% CI [-2.42, -1.07] P < .00001) compared with conventional treatment.
XNJi is effective in treating acute cerebral hemorrhage with significant improvement of CSS, NHISS and impairment of hs-crp, hematoma, and edema compared with conventional treatment. Moreover, XNJi got remarkable efficacy at the dose of 20, 30, 60 mL and from 7 to 28 days. No serious adverse reactions occurred. These results were mainly based on small-sample and low-quality studies. Therefore, more rigorous, large-scale RCTs were further needed to confirm its efficacy, safety, and detailed characteristic of application.]]></abstract><cop>United States</cop><pub>the Author(s). Published by Wolters Kluwer Health, Inc</pub><pmid>32282713</pmid><doi>10.1097/MD.0000000000019648</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0025-7974 |
| ispartof | Medicine (Baltimore), 2020-04, Vol.99 (15), p.e19648-e19648 |
| issn | 0025-7974 1536-5964 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7220447 |
| source | Wolters Kluwer Open Health; MEDLINE; DOAJ Directory of Open Access Journals; IngentaConnect Open Access; PubMed Central; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Activities of Daily Living Acute Disease Adult Aged Aged, 80 and over Brain Edema - epidemiology C-Reactive Protein - analysis C-Reactive Protein - drug effects Cerebral Hemorrhage - drug therapy Cerebral Hemorrhage - epidemiology Drugs, Chinese Herbal - administration & dosage Drugs, Chinese Herbal - adverse effects Drugs, Chinese Herbal - therapeutic use Female Glasgow Coma Scale - statistics & numerical data Hematoma Humans Injections Male Middle Aged Nervous System Diseases - epidemiology Nervous System Diseases - physiopathology Randomized Controlled Trials as Topic Systematic Review And Meta-Analysis |
| title | Role of Xingnaojing Injection in treating acute cerebral hemorrhage: A systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A26%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20Xingnaojing%20Injection%20in%20treating%20acute%20cerebral%20hemorrhage:%20A%20systematic%20review%20and%20meta-analysis&rft.jtitle=Medicine%20(Baltimore)&rft.au=Ma,%20Xiao&rft.date=2020-04-01&rft.volume=99&rft.issue=15&rft.spage=e19648&rft.epage=e19648&rft.pages=e19648-e19648&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000019648&rft_dat=%3Cpubmed_cross%3E32282713%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32282713&rfr_iscdi=true |